



Used in Lieu of PTO/SB/08A/B
(Based on PTO 11-07 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/586,627	
			Filing Date	June 20, 2007	
			First Named Inventor	Tomas Cihlar	
			Art Unit	1614	
			Examiner Name	Not Assigned	
Sheet	1	of	2	Attorney Docket Number	599.PFUS

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-6,468,737	10-22-2002	Mason et al.	
	AB*	US-20030229225-A1	12-11-2003	Reddy et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	† ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-02/08241	01-31-2002	Gilead Sciences Inc et al.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Used in Lieu of PTO/SB/08A/B
(Based on PTO 11-07 version)

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/586,627		
		Filing Date	June 20, 2007		
		First Named Inventor	Tomas Cihlar		
		Art Unit	1614		
		Examiner Name	Not Assigned		
Sheet	2	of	2	Attorney Docket Number	599.PFUS

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	ANDREI et al. "Antiproliferative Effects of Acyclic Nucleoside Phosphonates on Human Papillomavirus (HPV)-Harboring Cell Lines Compared with HPV-Negative Cell Lines" <i>Oncology Research</i> , 10:523-531, (1998)	
	CB	D.L. FINE et al. "Cell Culture Factors Influencing In Vitro Expression of Mouse Mammary Tumor Virus," <i>In Vitro</i> , 12(10):693-701 (1976)	
	CC	HOLY, Antonini "Synthesis and Biological Activity of Isopolar Acyclic Nucleotide Analogs," <i>Recent Advances in Nucleosides: Chemistry and Chemotherapy</i> , 167-238 (2002)	
	CD	JOPLIN et al. "Dutular Expression of Autoantigens in Primary Biliary Cirrhosis," <i>Seminars in Liver Disease</i> , 17(2):97-102 (1997)	
	CE	KAST, R.E., "Tenofovir, COX Inhibitors and Zileuton During Cancer Immunotherapies: Up-Regulated TNF-Alpha Increases Antigen Driven Lymphocyte Proliferation," <i>Molecular Immunology</i> , 40:297-303 (2003)	
	CF	KEEFE et al. "Advances in Liver Disease" Highlights from the 54th Annual Meeting of the American Association for the Study of Liver Diseases, October 24-28, 2003, <i>Review in Gastroenterological Disorders</i> 2004, United States, 4(1):36-42	
	CG	KEOGH et al. "Human Retrovirus Associated with Aberrant Distribution Dihydrolipoamide Acetyl Transferase Component of Pyruvate Dehydrogenase Complex in Primary Biliary Cirrhosis," <i>Hepatology</i> , AASLD ABSTRACTS, 1350, October 2002 p. 500A	
	CH	LEE et al. "Treatment of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: Use of Ursodeoxycholic Acid," <i>Current Gastroenterology Reports</i> , 1:38-41 (1999)	
	CI	LIU et al. "Identification of a Proviral Structure in Human Breast Cancer," <i>Cancer Research</i> , 61:1754-1759 (2001)	
	CJ	MASON et al. "Pilot Study of Single and Combination Anti-Retroviral Therapy in Patients with Primary Biliary Cirrhosis," <i>Hepatology, Late Breaking Abstracts</i> , 38(5):1324 (2003)	
	CK	MASON, Andrew "Primary Biliary Cirrhosis: New Thoughts on Pathophysiology and Treatment," <i>Current Gastroenterology Reports</i> , 4:45-51 (2002)	
	CL	NEUBERGER, James "Primary Biliary Cirrhosis," <i>The Lancet</i> , 350:875-879, (1997)	
	CM	NISHIO et al. "Comparative Studies of Antimitochondrial Autoantibodies in Sera and Bile in Primary Biliary Cirrhosis," <i>Hepatology</i> , Vol. 25, No. 5, pp. 1085-1089 (1997)	
	CN	O'NEIL, M et al. "The Merck Index Thirteenth Edition" 2001, Merck & Co. Inc. Whitehouse Station, N.J. XP002328456, page 1631. col. 2- page 1632, col. 1	
	CO	O'NEIL, M. et al. "The Merck Index Thirteenth Edition" 2001. Merck & Co. Inc. Whitehouse Station, N.J. XP002328457, page 29, col. 1	
	CP	WALSH et al. "Successful Treatment with Adefovir Dipivoxil in a Patient with Fibrosing Cholestatic Hepatitis and Lamivudine Resistant Hepatitis B Virus," <i>GUT</i> 49:436-440 (2001)	
	CQ	WANG et al. "Detection of Mammary Tumor Virus ENV Gene-Like Sequences in Human Breast Cancer," <i>Cancer Research</i> 55:5173-579 (1995)	
	CR	WU et al. "Monoclonal Antibody-Mediated Inhibition of HIV-1 Reverse Transcriptase Polymerase Activity," <i>The Journal of Biological Chemistry</i> , 268(14):9980-9985 (1993)	
	CS	XU et al. "Does a Betaretrovirus Infection Trigger Primary Biliary Cirrhosis?" <i>PNAS</i> , 100(14):8454-8459	
Examiner Signature			Date Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.